Free Biotech Stock Directory, Pharma Stocks, Telehealth Stocks, Medtech Stocks.

4SC (XETRA: VSC.DE) is an innovative biotechnology company focused on clinical development.We discover and develop targeted small molecule drugs with epigenetic modes of action for the treatment of cancers in indications with high unmet medical need and significant economic potential.
Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is a leader in developing patient-specific expanded cell therapies for the treatment of patients with serious diseases and conditions.Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement.Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee joint, and ixmyelocel-T, a treatment for advanced stage disease due to ischemic dilated cardiomyopathy Patient-specific multicellular therapy in heart failure.

biotech stock1
AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company formed in 2013 following a spin-off from Abbott Laboratories.The company’s mission is to use its expertise, dedicated employees and unique innovative approach to develop and market advanced therapies to address some of the world’s most complex and serious diseases.Together with its wholly-owned subsidiary Pharmacyclics, AbbVie employs more than 28,000 people worldwide and sells medicines in more than 170 countries.
Abbott (NYSE: ABT) is a global healthcare company dedicated to improving lives by developing products and technologies that span the healthcare spectrum.With a leading scientific portfolio of diagnostics, medical devices, nutritionals and branded generics, Abbott serves people in more than 150 countries and employs approximately 69,000 people.76
Abeona Therapeutics Inc. (NasdaqCM:ABEO) develops and delivers gene therapy and plasma-based products for serious and life-threatening rare diseases.Abeona’s lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIB and IIIA).We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Barton disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disease using a novel CRISPR/Cas9-based gene editing approach Conduct gene therapy programs for rare blood disorders.In addition, we are developing rare plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for the treatment of hereditary COPD using our proprietary SDF™ (salt diafiltration) ethanol-free process.
ABIVAX (EURONEXT:ABVX) is an innovative biotechnology company focused on targeting the immune system to eliminate viral diseases.ABIVAX utilizes three technology platforms for drug discovery: antiviral, immune enhancement and polyclonal antibody platforms.ABX464, its most advanced compound, is currently in Phase 2 clinical trials to provide a functional cure for HIV/AIDS patients.It is a first-in-class oral antiviral small molecule that blocks HIV replication through a unique mechanism of action and has strong anti-inflammatory properties.Additionally, ABIVAX is advancing clinical stage immune enhancers as well as multiple preclinical drug candidates against other viral targets (i.e. Chikungunya, Ebola, Dengue), with some compounds planned to enter clinical development within the next 18 months stage.


Post time: Jun-13-2022